Literature DB >> 10479482

A type 2 diabetes-associated polymorphic ARE motif affecting expression of PPP1R3 is involved in RNA-protein interactions.

J Xia1, C Bogardus, M Prochazka.   

Abstract

We have previously described a polymorphism in the 3' untranslated region (UTR) of the PPP1R3 gene that encodes the muscle-specific glycogen-targeting regulatory PP1 subunit. This polymorphism alters the distance between two putative mRNA-destabilizing ATTTA (AUUUA) motifs and is distinguished by a 10-nucleotide (allele ARE1) vs a 2-nucleotide interval (allele ARE2). ARE2 is associated with insulin resistance as well as increased prevalence of type 2 diabetes in the Pima Indians, and correlates with reduced expression of this subunit in vivo, causing a 10-fold half-life reduction of reporter mRNA in NIH3T3 cells. Gel shift assays, Northwestern blotting, and RNA-protein UV crosslinking revealed three proteins (43, 80, and 139 kDa) binding to the polymorphic ARE region in these cells. The interactions are sequence specific, and can be suppressed by an unlabeled competitor in a dose-dependent manner. The less stable ARE2 allele shows at least 2-fold higher relative protein binding, indicating that the polymorphic ARE region has a mRNA-destabilizing role. We suggest that the increased protein binding to ARE2 contributes to a faster degradation of PPP1R3 mRNA carrying this allele, and the resulting lower concentration of the protein contributes to insulin resistance, thus increasing the risk for development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479482     DOI: 10.1006/mgme.1999.2884

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  Single nucleotide polymorphisms within functional regions of genes implicated in insulin action and association with the insulin resistant phenotype.

Authors:  Malgorzata Malodobra; Agnieszka Pilecka; Bohdan Gworys; Rajmund Adamiec
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

Review 2.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

Review 3.  Genetic variants in mRNA untranslated regions.

Authors:  Maristella Steri; M Laura Idda; Michael B Whalen; Valeria Orrù
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-03-26       Impact factor: 9.957

4.  A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice.

Authors:  David B Savage; Lanmin Zhai; Balasubramanian Ravikumar; Cheol Soo Choi; Johanna E Snaar; Amanda C McGuire; Sung-Eun Wou; Gemma Medina-Gomez; Sheene Kim; Cheryl B Bock; Dyann M Segvich; Bhavana Solanky; Dinesh Deelchand; Antonio Vidal-Puig; Nicholas J Wareham; Gerald I Shulman; Fredrik Karpe; Roy Taylor; Bartholomew A Pederson; Peter J Roach; Stephen O'Rahilly; Anna A DePaoli-Roach
Journal:  PLoS Med       Date:  2008-01-29       Impact factor: 11.069

5.  Male preponderance in early diagnosed type 2 diabetes is associated with the ARE insertion/deletion polymorphism in the PPP1R3A locus.

Authors:  Alex S F Doney; Bettina Fischer; Joanne E Cecil; Patricia T W Cohen; Douglas I Boyle; Graham Leese; Andrew D Morris; Colin N A Palmer
Journal:  BMC Genet       Date:  2003-06-28       Impact factor: 2.797

6.  Positional cloning of "Lisch-Like", a candidate modifier of susceptibility to type 2 diabetes in mice.

Authors:  Marija Dokmanovic-Chouinard; Wendy K Chung; Jean-Claude Chevre; Elizabeth Watson; Jason Yonan; Beebe Wiegand; Yana Bromberg; Nao Wakae; Chris V Wright; John Overton; Sujoy Ghosh; Ganesh M Sathe; Carina E Ammala; Kathleen K Brown; Rokuro Ito; Charles LeDuc; Keely Solomon; Stuart G Fischer; Rudolph L Leibel
Journal:  PLoS Genet       Date:  2008-07-25       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.